Abstract:Aims:This study aims to investigate and validate the potential drug target to HDAC1.Background:Human histone deacetylase 1 (HDAC1) can catalyze the deacetylation of histones belonging to the family of human histone deacetylases (HDACs). Amide hydrolase HDAC1 plays a key role in the development of many serious cancers such as prostate cancer, gastric cancer, lung cancer, esophageal cancer, colon cancer, and breast cancer. Therefore, HDAC1 inhibitors, promoting the transcription of a series of key genes such as the p53 gene and inhibiting the development of cancer through various downstream mechanisms, have great potential for the treatment of cancer.Objective:The objective of this study is to discover new skeleton HDAC1 inhibitors efficiently and conveniently with therapeutic potential for cancer.Method:Based on the crystal structure of HDAC1, through the combination of receptor-based and ligand- based virtual screening from the commercial compound library, the top-ranked compounds are selected for purchase through binding modes analysis, and their activities were verified through in vitro HDAC1 inhibitory biological experiments.Results:Based on LeDock, 5ICN showed good distinguishing ability and was used as the receptor. According to the results of the LeDock docking scoring from receptor-based virtual screening, 69 compounds with binding energy less than -7.5 kcal/mol were obtained and used for ligand-based virtual screening. A total of 21 novel compounds with high potential HDAC1 inhibitory activity were collected by combining the similarity searching (NN) and the multinomial Naive Bayes machine learning model (NB) methods. Through binding modes analysis, 10 compounds with different structures with potential HDAC1 inhibitory activity were selected and screened HDAC1 inhibitory in vitro. May267 showed moderate HDAC1 inhibitory activity, and the inhibition rate was 48% at a concentration of 20 μM.Conclusion:This study discovers novel small molecule HDAC1 inhibitors by combined receptor-based and ligand-based virtual screening strategy, which provides an efficient method for the discovery of other small molecule drugs. May267 shows moderate HDAC1 inhibitory activity, which can be further optimized as a lead compound. However, it still has the problem of poor kinase selectivity to be solved.

Developing Spindlin1 Small-Molecule Inhibitors by Using Protein Microarrays.

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.

Molecular Basis for SPIN·DOC-Spindlin1 Engagement and Its Role in Transcriptional Inhibition

Identification and Characterization of Benzo[d]oxazol-2(3H)-one Derivatives As the First Potent and Selective Small-Molecule Inhibitors of Chromodomain Protein CDYL

Structure-guided development of YEATS domain inhibitors by targeting pi-pi-pi stacking.

Specific pupylation as IDEntity reporter (SPIDER) for the identification of protein-biomolecule interactions

Selective inhibition of BET bromodomains

Structural diversity of the epigenetics pocketome

Structure-guided Development of YEATS Domain Inhibitors by Targeting Π-Π-π Stacking

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Identifying The Proteins To Which Small-Molecule Probes And Drugs Bind In Cells

Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Design and discovery of monopolar spindle kinase 1 (MPS1/TTK) inhibitors by computational approaches

Large-scale Screening of I-Motif Binding Compounds in the Silkworm, Bombyx Mori.

Construction of a synthetic methodology-based library and its application in identifying a GIT/PIX protein–protein interaction inhibitor

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy

Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1)

Molecular basis for SPINDOC-Spindlin1 engagement and its role in transcriptional attenuation

Kinetic and High-Throughput Profiling of Epigenetic Interactions by 3D-Carbene Chip-Based Surface Plasmon Resonance Imaging Technology